Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
코로나19 환자를 위한 지방유래 중간엽줄기세포의 임상적 사용 근거
Review
[키워드] acute respiratory distress
acute respiratory distress syndrome
administration
alveolar fluid clearance
animal model
animal models
antimicrobial
ARDS
ASC
benefit
breath
capital city
Cell
China
Clinical studies
clinical study
Clinical use
Comorbidity
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 disease
COVID-19 outbreak
COVID-19 patient
Critical
demonstrated
distress
edema
effective
Ex vivo
Fever
global pandemic
globe
greater
Health Organization
healthcare
high mortality rate
hospital resources
human clinical trials
human lung
hypoxia
illness
immune response
immune responses
immunomodulatory activities
in some
in vivo
Inflammation
inhibit
intravenous
Intravenous administration
intravenous route
lead
Local
lung
lung damage
Lungs
majority
Mesenchymal stem cells
molecules
morbidity
morbidity and mortality
MSC
MSCs
multi-organ failure
Multiple
Novel coronavirus
older patients
Pain
Patient
patient mortality
per day
Pneumonia
pulmonary disease
Pulmonary edema
Pulmonary function
rationale
reduce
reduced
respiratory
respiratory distress
respiratory symptoms
risk
Safe
SARS-CoV-2
SARS-COV-2 infection
severe disease
Severe respiratory distress
stem cell
stem cells
syndrome
therapeutic option
therapy
Travel
Treatment
treatment of COVID-19
Viral
viral outbreak
viral respiratory
with COVID-19
World Health Organization
Wuhan
[DOI] 10.1186/s12967-020-02380-2 PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s12967-020-02380-2 PMC 바로가기 [Article Type] Review